Skip to content

Study · In vitro (cell-free) · 2020

7 results

Identification of Binding Sites on Human Serum Albumin for Somapacitan, a Long-Acting Growth Hormone Derivative.

Johansson E, Nielsen AD, Demuth H, Wiberg C, Schjødt CB, Huang T, Chen J, Jensen S, Petersen J, Thygesen P

Biochemistry30 Mar 2020Cited by 28 (Europe PMC)

PMID32208682 (opens in a new tab)DOI10.1021/acs.biochem.0c00019 (opens in a new tab)PepBankPUB-32208682
Source linkPubMedAsk about this study
Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

5 results from studies that gave the peptide. No result from this study comes from people.

  1. 01LabIn vitro (cell-free)Activity measurement

    In albumin binding assays, one somapacitan molecule bound HSA with high affinity of approximately 100-1000 nM.

    In plain wordsIn lab tests, one somapacitan molecule bound strongly to human serum albumin.

    Peptide
    Somapacitan
    Outcome
    Not applicableHigh-affinity HSA binding
    Study

    n: not reported in source

    Human serum albumin binding assays
    Outcome group
    Receptor activity and mechanism · Pharmacology
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Isothermal titration calorimetry (ITC) binding profiles showed high-affinity binding (∼100-1000 nM) of one somapacitan molecule and low-affinity binding (∼1000-10000 nM) of one to two somapacitan molecules to HSA.
  2. 02LabIn vitro (cell-free)Activity measurement

    In albumin binding assays, one to two somapacitan molecules bound HSA with low affinity of approximately 1000-10000 nM.

    In plain wordsIn lab tests, one to two somapacitan molecules bound more weakly to human serum albumin.

    Peptide
    Somapacitan
    Outcome
    Not applicableLow-affinity HSA binding
    Study

    n: not reported in source

    Human serum albumin binding assays
    Outcome group
    Receptor activity and mechanism · Pharmacology
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Isothermal titration calorimetry (ITC) binding profiles showed high-affinity binding (∼100-1000 nM) of one somapacitan molecule and low-affinity binding (∼1000-10000 nM) of one to two somapacitan molecules to HSA.
  3. 03LabIn vitro (cell-free)Activity measurement

    In SEC and ITC assays, the high-affinity somapacitan binding site was in HSA domain III.

    In plain wordsIn lab tests, somapacitan's high-affinity binding site was in albumin domain III.

    Peptide
    Somapacitan
    Outcome
    Not applicableHigh-affinity binding location
    Study

    n: not reported in source

    Human serum albumin binding assays
    Outcome group
    Receptor activity and mechanism · Pharmacology
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The high-affinity site was identified in HSA domain III using size exclusion chromatography (SEC) and ITC.
  4. 04LabIn vitro (cell-free)Activity measurement

    In a crystal structure with modified HSA, somapacitan occupied low-affinity fatty acid-binding site 6 in domain II.

    In plain wordsIn lab tests, somapacitan bound a low-affinity site in domain II of modified albumin.

    Peptide
    Somapacitan
    Outcome
    Not applicableLow-affinity binding location
    Study

    n: not reported in source

    Human serum albumin binding assays
    Outcome group
    Receptor activity and mechanism · Pharmacology
    Studied dose
    Dose not stated

    Source sentences

    Summary
    A crystal structure of somapacitan in complex with HSA optimized for neonatal Fc receptor binding, having four amino acid residue replacements, identified a low-affinity site in fatty acid-binding site 6 (domain II).
  5. 05LabIn vitro (cell-free)Activity measurement

    In scattering and SPR assays, results supported two somapacitan binding sites on HSA.

    In plain wordsIn lab tests, results supported two somapacitan binding sites on albumin.

    Peptide
    Somapacitan
    Outcome
    Not applicableNumber of HSA binding sites
    Study

    n: not reported in source

    Human serum albumin binding assays
    Outcome group
    Receptor activity and mechanism · Pharmacology
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Furthermore, small-angle X-ray scattering and SPR brace two somapacitan-binding sites on HSA.

Studies that did not test the peptide alone2

In this study, Somapacitan was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Somapacitan.

  1. 06LabNot a test of Somapacitan aloneIn vitro (cell-free)Activity measurement

    In SEC assays, the neonatal Fc receptor shielded one somapacitan binding site in HSA domain III.

    In plain wordsIn lab tests, the neonatal Fc receptor shielded one somapacitan binding site on albumin.

    Peptide
    Somapacitan
    Outcome
    Not applicableFc receptor shielding
    Study

    n: not reported in source

    Human serum albumin binding assays
    Outcome group
    Receptor activity and mechanism · Pharmacology

    Source sentences

    Summary
    SEC studies showed that the neonatal Fc receptor shields one binding site for somapacitan, indicating its position in domain III.

    In this study, Somapacitan was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Somapacitan.

  2. 07LabNot a test of Somapacitan aloneIn vitro (cell-free)Activity measurement

    In SPR assays, HSA residue replacements affected high-affinity somapacitan binding kinetics.

    In plain wordsIn lab tests, changes to albumin affected the speed of high-affinity somapacitan binding.

    Peptide
    Somapacitan
    Outcome
    Not applicableBinding kinetics with modified HSA
    Study

    n: not reported in source

    Human serum albumin binding assays
    Outcome group
    Receptor activity and mechanism · Pharmacology

    Source sentences

    Summary
    Surface plasmon resonance (SPR) showed these replacements affect the kinetics of the high-affinity binding site.
    1 context sentence
    Summary · context
    A crystal structure of somapacitan in complex with HSA optimized for neonatal Fc receptor binding, having four amino acid residue replacements, identified a low-affinity site in fatty acid-binding site 6 (domain II).

    In this study, Somapacitan was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Somapacitan.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.